The Global Dementia Drugs Market, by Drug Class (MAO Inhibitors, Cholinesterase Inhibitors, and Glutamate Inhibitors), and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others) is estimated to be valued at US$ 13,900.0 million in 2017and is projected to exhibit a CAGR of 8.4% over the forecast period (2018 - 2026).
People suffering from early stage of Alzheimer’s disease with dementia do not have appropriate access to healthcare infrastructure for diagnosis and treatment of the disease. For instance, according to World Alzheimer Report in 2016, only around 50% patients suffering from dementia undergo diagnosis. The rate of underdiagnoses is 10% in low- and middle-income economies. This is expected to propel growth of the dementia drugs market. As of 2011, there were no standard guidelines for diagnosis of disease. Currently, biomarker tests involving amount of beta-amyloid in the brain, which can be visualized in positron emission tomography imaging are under research to diagnosis develop treatment for Alzheimer’s disease.
Browse 25 Market Data Tables and 44 Figures spread through 173 Pages and in-depth TOC on "Dementia Drugs Market, by Drug Class (MAO Inhibitors, Cholinesterase Inhibitors, and Glutamate Inhibitors), and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others) - Global Forecast to 2026"
To know the latest trends and insights related to dementia drugs market, click the link below:
The market landscape is set to undergo rapid changes in the following decade, driven by advancing diagnostic capabilities and growing awareness. Disease-modifying mechanisms are expected to enhance the treatment of this neurodegenerative condition. As a global push is made for early diagnosis and treatment, the surge in dementia cases will require effective therapies. Manufacturers are increasingly focusing on receiving FDA approvals for their products, in turn boosting market growth. For instance, in September 2017, Zydus Cadila announced that it received a final nod from the U.S. health regulator to market Donepezil Hydrochloride tablets used for the treatment of dementia of the Alzheimer’s type in the U.S. Various companies are developing novel drugs to strengthen their foothold in the market. For instance, Merck and Company bought an exclusive worldwide license from Japan's Teijin Pharma in 2016, to develop an investigational, preclinical anti-tau antibody, which has disease-modifying potential. Genentech and AC immune are also developing anti-tau antibody. In 2017, TauRx announced phase three results of investigational drug LMTX first tau aggregation inhibitor for Alzheimer’s disease.
Moreover, increasing approvals by regulatory agencies is expected to boost market growth. For instance, in January 2018, FDA proposed new guidelines aimed at lowering the clinical study goals of Alzheimer's disease drugs for treating earlier-stage patients who have not yet showed functional disability or clinical abnormality. This is part of efforts to expand access to safe and effective treatment options for serious conditions, including Alzheimer’s disease through accelerated approval for such drugs. However, failure of drugs in late stages of clinical trials is the major factor hampering growth of the market. In 2012, Pfizer Inc. and Johnson & Johnson, announced plans to discontinue the development of Alzheimer drug, which was in intravenous (IV) form—bapineuzumab—as drug failed to help patients with memory robbing condition in a second high profile clinical trial. Such failures, deter the expected growth of the market. Dementia market also faces difficulty expanding in certain regions. For instance, in the U.K., issues related to cost-effectiveness of cholinesterase inhibitors impelled the Clinical Excellence and National Institute of Health to edge reimbursements to patients with moderate AD. Additionally, they limit the prescriptions of moderate AD valid only through neurologists, which are usually referred to the patients at later disease stage. Thus, use of these drugs are comparatively less in Europe, however, drug-modifying drugs may gain traction in this region in near future.
Key takeaways of the dementia drugs market: